Achieving a Good Response in Myxofibrosarcoma With Uncontrollable Bleeding Using an Enzyme-Targeting
Kana Kobayashi1, Yasuhiro Ogawa2, Ryosuke Bessho3
1Division of Radiation Oncology, Kobe University Hospital, Kobe, JPN.
Cureus
|February 24, 2025
Summary
Kochi oxydol radiation therapy for unresectable carcinomas (KORTUC) showed effectiveness in treating a recurrent myxofibrosarcoma in a patient unsuitable for surgery. This case highlights KORTUC
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Myxofibrosarcoma is a common soft tissue sarcoma of the extremity.
- Post-operative radiation therapy is a standard treatment modality.
- Surgical intervention is often the primary treatment for soft tissue sarcomas.
Observation:
- A 78-year-old male presented with a large, recurrent myxofibrosarcoma on his forearm.
- The patient refused surgical treatment due to tumor size and location.
- The tumor exhibited repeated recurrences and bleeding over seven years.
Findings:
- Kochi oxydol radiation therapy for unresectable carcinomas (KORTUC) involves topical application (KORTUC I) and injection (KORTUC II) of hydrogen peroxide solution.
- The patient was treated with both KORTUC I and KORTUC II for the unresectable myxofibrosarcoma.
- A favorable response to KORTUC treatment was observed, managing tumor recurrence and bleeding.
Implications:
- This case suggests KORTUC may be an effective treatment option for myxofibrosarcoma, particularly in patients unsuitable for surgery.
- Limited reports exist on KORTUC for sarcomas, indicating a need for further research.
- Future studies should explore KORTUC's efficacy in managing unresectable or recurrent soft tissue sarcomas.
Keywords:
bleedingenzyme-targeting radiosensitizationexternal beam radiotherapyhydrogen peroxidekortucmyxofibrosarcomatumor hypoxia

